Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3
IntroductionNeuroendocrine neoplasms (NEN) are a rare and heterogenous group of tumors arising from neuroendocrine cells in multiple organs. Neuroendocrine tumors (NET) G3 encompass a small subgroup accounting for less than 10% of all neuroendocrine neoplasms. In contrast to NET G1 and G2 as well as...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1285529/full |
| _version_ | 1797362438652297216 |
|---|---|
| author | Martina Hinterleitner Martina Hinterleitner Martina Hinterleitner Ruben Pfeiffer Nils F. Trautwein Nils F. Trautwein Bence Sipos Bence Sipos Bence Sipos Stephan Singer Stephan Singer Silvio Nadalin Silvio Nadalin Alfred Königsrainer Alfred Königsrainer Ulrich M. Lauer Ulrich M. Lauer Ulrich M. Lauer Ulrich M. Lauer Christian la Fougère Christian la Fougère Christian la Fougère Christian la Fougère Lars Zender Lars Zender Lars Zender Lars Zender Clemens Hinterleitner Clemens Hinterleitner Clemens Hinterleitner Clemens Hinterleitner |
| author_facet | Martina Hinterleitner Martina Hinterleitner Martina Hinterleitner Ruben Pfeiffer Nils F. Trautwein Nils F. Trautwein Bence Sipos Bence Sipos Bence Sipos Stephan Singer Stephan Singer Silvio Nadalin Silvio Nadalin Alfred Königsrainer Alfred Königsrainer Ulrich M. Lauer Ulrich M. Lauer Ulrich M. Lauer Ulrich M. Lauer Christian la Fougère Christian la Fougère Christian la Fougère Christian la Fougère Lars Zender Lars Zender Lars Zender Lars Zender Clemens Hinterleitner Clemens Hinterleitner Clemens Hinterleitner Clemens Hinterleitner |
| author_sort | Martina Hinterleitner |
| collection | DOAJ |
| description | IntroductionNeuroendocrine neoplasms (NEN) are a rare and heterogenous group of tumors arising from neuroendocrine cells in multiple organs. Neuroendocrine tumors (NET) G3 encompass a small subgroup accounting for less than 10% of all neuroendocrine neoplasms. In contrast to NET G1 and G2 as well as neuroendocrine carcinomas (NEC), in NET G3 data on treatment and patient outcomes are still limited. Especially in a metastasized tumor stage, the role of surgery, peptide receptor radionucleotide therapy (PRRT), and systemic chemotherapy is not clearly defined.MethodsIn this real-life cohort, we consecutively analyzed clinical outcome in NET G3 patients receiving different diagnostic and treatment.Results and discussionWe found that even metastasized NET G3 patients undergoing surgery, or receiving radiation, somatostatin analogues (SSA), and PRRT showed a clear survival benefit. Interestingly, all treatment regimen were superior to classical chemotherapeutic agents. In addition, somatostatin receptor (SSTR) PET-CT, FDG PET-CT, and repetitive biopsies were shown to be useful diagnostic and prognostic tools in NET G3. Our study demonstrates that patients with highly proliferative NET G3 might benefit from less aggressive treatment modalities commonly used in low proliferative NEN. |
| first_indexed | 2024-03-08T16:06:58Z |
| format | Article |
| id | doaj.art-f776dfeedfdc46f3b01b72156cb56fc2 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-08T16:06:58Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-f776dfeedfdc46f3b01b72156cb56fc22024-01-08T05:32:26ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-01-011410.3389/fendo.2023.12855291285529Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3Martina Hinterleitner0Martina Hinterleitner1Martina Hinterleitner2Ruben Pfeiffer3Nils F. Trautwein4Nils F. Trautwein5Bence Sipos6Bence Sipos7Bence Sipos8Stephan Singer9Stephan Singer10Silvio Nadalin11Silvio Nadalin12Alfred Königsrainer13Alfred Königsrainer14Ulrich M. Lauer15Ulrich M. Lauer16Ulrich M. Lauer17Ulrich M. Lauer18Christian la Fougère19Christian la Fougère20Christian la Fougère21Christian la Fougère22Lars Zender23Lars Zender24Lars Zender25Lars Zender26Clemens Hinterleitner27Clemens Hinterleitner28Clemens Hinterleitner29Clemens Hinterleitner30Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, GermanyEuropean Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, GermanyGerman Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 ‘Image-Guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen, Tuebingen, GermanyDepartment of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, GermanyEuropean Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, GermanyDepartment of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, GermanyDepartment of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, GermanyEuropean Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, GermanyGerman Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 ‘Image-Guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen, Tuebingen, GermanyEuropean Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, GermanyDepartment of Pathology, University Hospital Tuebingen, Tuebingen, GermanyEuropean Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, GermanyDepartment of General and Transplant Surgery, University Hospital Tuebingen, Tuebingen, GermanyEuropean Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, GermanyDepartment of General and Transplant Surgery, University Hospital Tuebingen, Tuebingen, GermanyDepartment of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, GermanyEuropean Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, GermanyGerman Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 ‘Image-Guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen, Tuebingen, GermanyGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Tuebingen, GermanyEuropean Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, GermanyGerman Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 ‘Image-Guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen, Tuebingen, GermanyDepartment of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, GermanyGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Tuebingen, GermanyDepartment of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, GermanyEuropean Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, GermanyGerman Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 ‘Image-Guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen, Tuebingen, GermanyGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Tuebingen, GermanyDepartment of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, GermanyEuropean Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, GermanyGerman Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 ‘Image-Guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen, Tuebingen, GermanyCancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesIntroductionNeuroendocrine neoplasms (NEN) are a rare and heterogenous group of tumors arising from neuroendocrine cells in multiple organs. Neuroendocrine tumors (NET) G3 encompass a small subgroup accounting for less than 10% of all neuroendocrine neoplasms. In contrast to NET G1 and G2 as well as neuroendocrine carcinomas (NEC), in NET G3 data on treatment and patient outcomes are still limited. Especially in a metastasized tumor stage, the role of surgery, peptide receptor radionucleotide therapy (PRRT), and systemic chemotherapy is not clearly defined.MethodsIn this real-life cohort, we consecutively analyzed clinical outcome in NET G3 patients receiving different diagnostic and treatment.Results and discussionWe found that even metastasized NET G3 patients undergoing surgery, or receiving radiation, somatostatin analogues (SSA), and PRRT showed a clear survival benefit. Interestingly, all treatment regimen were superior to classical chemotherapeutic agents. In addition, somatostatin receptor (SSTR) PET-CT, FDG PET-CT, and repetitive biopsies were shown to be useful diagnostic and prognostic tools in NET G3. Our study demonstrates that patients with highly proliferative NET G3 might benefit from less aggressive treatment modalities commonly used in low proliferative NEN.https://www.frontiersin.org/articles/10.3389/fendo.2023.1285529/fullneuroendocrine tumorgradingG3somatostatin receptorPETtreatment |
| spellingShingle | Martina Hinterleitner Martina Hinterleitner Martina Hinterleitner Ruben Pfeiffer Nils F. Trautwein Nils F. Trautwein Bence Sipos Bence Sipos Bence Sipos Stephan Singer Stephan Singer Silvio Nadalin Silvio Nadalin Alfred Königsrainer Alfred Königsrainer Ulrich M. Lauer Ulrich M. Lauer Ulrich M. Lauer Ulrich M. Lauer Christian la Fougère Christian la Fougère Christian la Fougère Christian la Fougère Lars Zender Lars Zender Lars Zender Lars Zender Clemens Hinterleitner Clemens Hinterleitner Clemens Hinterleitner Clemens Hinterleitner Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3 Frontiers in Endocrinology neuroendocrine tumor grading G3 somatostatin receptor PET treatment |
| title | Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3 |
| title_full | Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3 |
| title_fullStr | Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3 |
| title_full_unstemmed | Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3 |
| title_short | Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3 |
| title_sort | treatment modalities favoring outcome in well differentiated neuroendocrine tumors g3 |
| topic | neuroendocrine tumor grading G3 somatostatin receptor PET treatment |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1285529/full |
| work_keys_str_mv | AT martinahinterleitner treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT martinahinterleitner treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT martinahinterleitner treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT rubenpfeiffer treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT nilsftrautwein treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT nilsftrautwein treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT bencesipos treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT bencesipos treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT bencesipos treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT stephansinger treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT stephansinger treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT silvionadalin treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT silvionadalin treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT alfredkonigsrainer treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT alfredkonigsrainer treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT ulrichmlauer treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT ulrichmlauer treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT ulrichmlauer treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT ulrichmlauer treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT christianlafougere treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT christianlafougere treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT christianlafougere treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT christianlafougere treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT larszender treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT larszender treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT larszender treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT larszender treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT clemenshinterleitner treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT clemenshinterleitner treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT clemenshinterleitner treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 AT clemenshinterleitner treatmentmodalitiesfavoringoutcomeinwelldifferentiatedneuroendocrinetumorsg3 |